Clinical Signiifcance of ROS1 Rearrangements in Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2013.12.09
- VernacularTitle:非小细胞肺癌中ROS1基因重排及其临床意义
- Author:
XU LUTING
1
;
ZHAO RUIJING
;
DONG ZENGJUN
;
ZHU TIENIAN
Author Information
1. 赛信通 上海 生物试剂有限公司
- Keywords:
ROS1 receptor tyrosine kinase;
Anaplastic lymphoma kinase;
Lung neoplasms;
Crizotinib;
Personal-ized medicine
- From:
Chinese Journal of Lung Cancer
2013;(12):663-670
- CountryChina
- Language:Chinese
-
Abstract:
Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in multiple malignancies, including non-small cell lung cancer (NSCLC). ROS1 rearrangement defines a new molecular subset of NSCLC with the prevalence of ROS1 rearrangements around 1%-2%. ROS1-positive NSCLCs arise in young never-smokers with adenocarcinoma that are similar to those observed in patients with ALK-rearranged NSCLC. Crizotinib demonstrates in vitro activity and early clinical trial shows marked antitumor activity in ROS1-rearranged patients. The overall response rate is around 56% and the disease control rate at 8 weeks is about 76%. Further understanding the ROS1 fusions in the pathogenesis of NSCLC, methods to detect ROS1 rearrangements, and targeting ROS1-rearranged NSCLC patients with specific kinase inhibitors would lead to an era of personalized medicine.
